Fukayna
Fulvestrant Injection
Strength
✓250 mg
Pack Size
1 PFS
Drug Class
Antiestrogens
Specification
USP/BP/IH Specs offered for exports
Storage
Store refrigerated at 2°C to 8°C.
Fukayna (fulvestrant) injection for intramuscular administration is an estrogen receptor antagonist.
The chemical name is
7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)-triene-3,17-beta-diol.
Fulvestrant is a white powder with a molecular weight of 606.77.
Fukayna is indicated for the treatment of
- Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy
- HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy
- HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine-based therapy or following disease progression on endocrine therapy
- HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy
Many breast cancers have estrogen receptors (ER) and the growth of these tumors can be stimulated by estrogen.
Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiol and downregulates the ER protein in human breast cancer cells.
Fulvestrant inhibited the growth of established MCF-7 xenografts and of tamoxifen-resistant breast tumor xenografts.
- Keep out of reach of children.
- Take as directed by physician.
A dose of 250 mg is recommended for patients with moderate hepatic impairment (Child-Pugh class B) to be administered intramuscularly into the buttock (gluteal area) slowly (1-2 minutes) as one 5 mL injection on Days 1, 15, 29, and once monthly thereafter.
The recommended dose of Fukayna is 250 mg to be administered intramuscularly into the buttocks (gluteal area) slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter.